.Attribute Medication, Posted online: thirteen September 2024 doi:10.1038/ s41591-024-03261-7In the non-randomized phase 3b/4 DESTINY-Breast12 research, trastuzumab deruxtecan (T-DXd) procedure of patients with HER2+ advanced bosom cancer cells as well as active or stable human brain metastases revealed consistent intracranial activity as well as systemic efficacy of T-DXd.